Last reviewed · How we verify
Hereditary angioneurotic edema
Approved treatments
- Orladeyo · Biocryst
Orladeyo works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms. - Firazyr · Sebastian Videla
- TAKHZYRO · DYAX CORP.
- Takhzyro · Dyax Corp
Lanadelumab-flyo binds and inhibits plasma kallikrein, reducing bradykinin generation and controlling angioedema in HAE. - Winstrol
- Kalbitor · Dyax Corp.
Kalbitor works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms. - Firazyr · Takeda
Firazyr works by blocking the action of bradykinin, a protein that causes blood vessels to swell and leads to symptoms of HAE.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hereditary angioneurotic edema patent landscape — cliff calendar, originator estates, attackable patents
- Hereditary angioneurotic edema treatment landscape brief
- Hereditary angioneurotic edema treatment updates RSS
Frequently asked questions about Hereditary angioneurotic edema
What drugs treat Hereditary angioneurotic edema?
Tracked treatments include Orladeyo, Firazyr, TAKHZYRO, Takhzyro, Winstrol, Kalbitor.
What is the treatment for Hereditary angioneurotic edema?
Standard treatment for Hereditary angioneurotic edema includes Orladeyo, Firazyr, TAKHZYRO, Takhzyro, Winstrol. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hereditary angioneurotic edema patent cliff · Hereditary angioneurotic edema CI report
- Treatment: Orladeyo · Biocryst
- Treatment: Firazyr · Sebastian Videla
- Treatment: TAKHZYRO · DYAX CORP.
- Treatment: Takhzyro · Dyax Corp
- Treatment: Winstrol
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing